Abstract. This work presents a study on the genetic profile of the left and right hemispheres of the brain of a mouse model of Parkinson's disease (PO). The goal is to characterize, in a genetic basis, PO as a disease that affects these two brain regions in different ways. Using the same wholegenome micro array expression data introduced by Brown et al. (2002) [1], we could find significant differences in the expression of some key genes, well-known to be involved in the mechanisms of dopamine production control and PD. The problem of selecting such genes was modeled as the MIN (a,/3)-FEATURE SET problem [2]; a similar approach to that employed previously to find biomarkers for different types of cancer using gene expression microarray data [3] . The Feature Selection method produced a series of genetic signatures for PO, with distinct expression profiles in the Parkinson's model and control mice experiments. In addition, a close examination of the genes composing those signatures shows that many of them belong to genetic pathways or have ontology annotations considered to be involved in the onset and development of PD. Such elements could provide new clues on which mechanisms are implicated in hemisphere differentiation in PD.
INTRODUCTION
Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by four main symptoms: resting tremors, rigidity of the limbs, slowness of movement, and difficulty with balance and coordination. The disease is caused by a continuous loss of the dopaminergic neurons in the substantia nigra of the brain. The degeneration of these neurons reduces the amount of dopamine produced, which interferes in the functioning of the basal ganglia -a region of the brain involved in the control of muscle action. Although the exact underlying cause of PD in not yet known, most scientists believe that genetics and/or environmental factors play an important role. Family history is gradually being perceived to be a risk factor, with an estimated 15-25% of the Parkinson's patients reporting having a relative with the disease. This view was initially confirmed in 1996, when a candidate gene for some cases of PD was mapped to chromosome 4 [4] . Since then, several other Parkinson's-related genes have been found. Also, a series of genetic pathways, in particular those related to apoptosis and neurodegeneration have also been implicated to PD. This work uses the same dataset introduced in Brown et al. (2002) [1] but goes one step further in terms of the analysis of results. While Brown et al. (2002) focuses in finding genes related to PD by comparing the brains of a PD model mouse against a control individual, in this work we aim at finding variations in gene expression between the left and right hemispheres of the mice brains. The dataset used comprises 7,035 genes and 80 experiments, corresponding to 40 voxels from a normal and 40 voxels from a Parkinson's affected rodent. It is available for download directly from the author's website 1 • The work of Brown provides extensive information on how the brain tissue samples were collected and how the microarray instance was generated. As these are not the central issues of this paper, we refer the reader directly to Brown's work.
The main method used to identify differentially expressed genes is based on a mathematical model for inference of gene expression patterns and NP-hard problem known as the MIN (a,j3)-FEATURE SET problem [3, 5] . This approach was previously used to identify genetic signatures for Alzheimer's disease [6] , as well as for the molecular classification of cancer [3, 7] . Genetic signatures obtained using this method carry a mathematical guarantee of inter-class differentiation and intra-class similarity, which lacks in other traditional approaches based solely on statistics, such as p-vaJue based selection. The MIN (a, J3)-FEATURE SET method is briefly described in the next section, but a more thorough discussion is found in reference [3) .
MODELING THE GENE SUBSET SELECTION PROBLEM
To understand how we address the problem of finding genetic markers for the two hemispheres of the PD brain, we will describe the MIN (a,j3)-FS problem, which provides a combinatorial formalization of the problem of interest. The MIN (a, J3)-FS problem is a variation of the well-known k-FEATURE SET and it has been introduced with the aim of selecting robust feature sets of strong discriminative power and withinclass similarity [5] . The problem is described as:
• Instance: A set of m examples X= {x( 1 l, ... , x(ml}, such that Vi= l, ... ,m; iiJ = {xii) ,4i), ... ,x~) ,t(il} E {N}n+l, and three integers k > 0, and a~ 1, J3 ~ 0.
• Question: Does there exist an (a, J3)-k-Feature SetS, S <;; { 1, · · · , n}, with lSI ~ k and such that:
-for all pairs of examples i i j, if t(il i tUl there exists S'(i,j) <;; S such that IS' I ~ a and for all/ E S' x}il i xfil ?
-for all pairs of examples i i j, if t(il = t(j) there exists S'(i,j) <;; S such that IS' I ~ J3 and for all/ E S' xjil = x}j) ?
The problem is NP-hard as the k-FEATURE SET problem is a special case where (a, J3) = ( 1, 0) [8] . Furthermore, the MIN (a, J3)-F S problem is not likely to be fixed-1 http:/!labs.pharrnacology.ucla.edulsmithlab/genome_multiplex/index.htm parameter tractable for parameter k as Cotta and Moscato (2003) have proved that the k-FEATURE SET problem is W[2]-complete [2] .
A fundamental distinction of the model used in this work, in relation to all previous applications, is that we take into account the fact that different regions of the brain are expected to have naturally distinct expression profiles due to normal tissue functional differentiation. Therefore, the aim of our approach becomes to find genes that are differentially expressed in the same voxel in the PD and normal brains. Under these circumstances, we will only work with the cases in which a): 1 and f3 = 0. Our aim is then to find a setS' of k features (genes) such that for any pair of samples with different targets (PD/normal, same voxel), there are at least a genes in S' that support (i.e. have distinctive expression levels) this difference in all voxels. In our tests, the parameter a was adjusted to return a solution with around 36 genes, which is the number of genes reported in Brown's work.
The notion of distinctive expression levels is a critical issue. Some gene expression studies consider two expression levels as significantly distinct if there is at least a 2-fold difference between them. Such difference is high enough to reduce the influence of noise and other precision limitations in the eDNA microarray technology. Therefore, given any two samples, relative to the same voxel, one from the PD and the other from the normal brain, we only consider that a gene is discriminative for that pair if the expression levels for the two samples differ by at least a 2-fold ratio.
As said before, the MIN (a,f3)-FEATURE SET Problem is NP-hard, but the use of a standard integer programming (IP) formulation, such as in references [3, 7] , in conjunction with the IP solver ILog CPLEX 9.0 2 , allows solving medium-sized instances to optimality in relatively short CPU times. To cite an exmple, the three optimal feature sets shown in Figure 2 were obtained in less than 5 minutes of CPU time each, using a Pentium IV 3.0 GHz computer with 1 Gb RAM.
PARKINSON'S DISEASE MICROARRAY DATA
The Parkinson's disease microarray data used in this work was introduced by Brown et al. (2002) [1] . They used a PD model created by the administration of toxic doses of methamphetamine to the C57BL/6J strain of mice 3 • These doses cause a destruction of the dopaminergic nerve, which is responsible for control movement initiation and coordination. The brains from the control and methamphetamine-treated mice were divided into 40 voxels each (ten volume slices taken horizontally, each divided into four voxels) and then analyzed, resulting in a 7,035-gene microarray with 80 samples.
Brown et al. (2002) reported 36 genes as differentially expressed in the brains of the PD and normal mice. The genes are listed in Figure 1 and will be used as benchmark for comparison against the ones selected using the MIN (a,/3)-FS method.
Gene symbol Accession# Name AA276158  AA222567  AA261393  AA253890  AA244536  AA238752  AA239485  AI894064  AA275664  AA240279  AA249976  AA017742  W97446  AA461637  AA472395  AA501045  AA212645  AA266975  AA240272  AA028410  W98195  AA268478  AA237378  AA239171  W49392  AA183927  AA245165  AA267952  AA260570  AA267965  AA266087  AA250181  AA119248  AA220551  AA221073  AA266938 ATP-binding cassette, sub-family A (ABCI ) 
COMPUTATIONAL RESULTS
The application of the MIN ( a,fJ)-FS method resulted in three genetic signatures for Parkinson's disease; one consisting of genes differentially expressed in the PD brain compared to the normal (Figure 2a ), using all samples; a second signature considering only the samples from the left hemisphere of the PD and normal brains ( Figure 2b) ; and the last signature considering only the right hemisphere samples (Figure 2c ).
As the biomarkers will be compared to the 36-gene signature from Brown et al. (2002), we adjusted the parameters of the MIN (a,/3)-FS approach to return optimal feature sets with the closest number of genes (probes). The parameters were (a,{J) = (9, 0) for the whole brain signature; (a,/3) = (10, 0) for the left hemisphere;
and (a, f3) = (11, 0) for the right hemisphere. 
Pathway analysis
An analysis of the pathways most represented in each of the signatures points to the MIN (a,f3)-FS method is as a better biomarker selection method. The study was conducted using a web-based tool -the GATHER [9] from Duke University, USA.
Next, we present the information retrieved using the pathway analysis tool and then we proceed to explain each of the findings. In Figure 3 we show the pathways most represented in the genetic signatures introduced in Brown et al. (2002) and in this work. Afterwards, we show current evidence of links between PD and the pathways present in Figure 3 . Between parenthesis, we list the signatures in which the pathway is represented • Glutamate metabolism (R) -The degeneration of dopaminergic neurons in the brain of PD patients has been linked to a malfunction of the complex interaction between dopaminergic and metabotropic glutamate receptors (mGluRs) [12] , or to glutamate-induced toxicity [ 13] .
• Glyoxylate and dicarboxylate metabolism (B, L) -No connection reported.
• Hedgefwg signaling (W, L, R) -The Hedgehog pathway has a role in several developmental processes and in the maintenance of adult organs and cell types, including neuronal subtypes [14] . This was recently confirmed by a stem cell study for mesodiencephalic dopaminergic neuron replacement that confirmed the importance of Fgf8 (fibroblast growth factor 8) and Shh (sonic hedgehog) for the development of such cells [15] .
• Insulin signaling (W, R) -The insulin signaling pathway has been linked to Parkinson's disease due the concentration of Igfl (insulin-like growth factor 1) receptors in the substantia nigra region [ 16] . Also, a recent study has shown that human brain endothelial cells are specially vulnerable to hyperglycemic stress, resulting in apoptosis. Activation of insulin signaling thus protects the cell integrity by maintaining cellular reduction-oxidation balance [17] .
• MAPK signaling (L)-This pathway has been directly involved in PD development by a study of a mutation in gene Lrrk2 (leucine-rich repeat kinase 2), which alters MAPK signaling cascades and triggers apoptosis, causing autosomal dominant Parkinson's disease [18] .
• Nitrogen metabolism (R) -Nitrogen metabolism is linked to PD by the toxic oxidative stress response mechanism, which triggers dopaminergic neuron death [19, 20] .
disease pathway is represented by Pink1
(pten-induced kinase 1), whose mutations cause autosomal recessive PD [21] .
• Peptidoglycan biosynthesis (R) -No connection reported.
• Purine metabolism (W, R) -Purine metabolism is closely connected to dopamine metabolism through adenosine, an endogenous purine nucleoside that regulates it. Recent studies have established adenosine receptor-dopamine receptor interactions in PD and suggest adenosine as a target for PD therapy [22] .
• Reductive carboxylate cycle (B) -No connection reported.
• Retinol metabolism (B) -Retinol metabolism is regulated by retinoic acid (RA) [23] , and recently RA was found to be involved in the regulation of plasticity and regeneration in the adult brain, possibly playing a role in motor disorders such as PD [24] .
• Sulfur metabolism (B) -Defects in sulphoxidation and sulphation of xenobiotics is a common hallmark of PD, indicating that endogenous sulphur metabolism is disturbed [25] . Xenobiotics effects on mitochondrial function have also been linked to neurotoxicity and apoptosis [26] .
• Tight junction (B, W) -Alterations in tight junction and in the blood-brain barrier change the integrity of the cell membrane and permeability. Several studies describe their relation to brain degeneration and PD [10, 27] .
From the 16 pathways cited in Figure 3 , 11 of them can be linked to neurodegeneration or Parkinson's disease. Also, the appearance of Parkinson's and Alzheimer's diseases pathways in the genetic signatures introduced in this work is worth mention- ing, as Brown's biomarkers missed both. In terms of relevant biomarkers, we must give special emphasis to Pinkl (pten-induced kinase 1), found in the left hemisphere signature and that is a well-known PD gene that protects the neuron from mitochondrial oxidative stress [21] . Also worth mentioning is gene Gsk3b (glycogen synthase kinase 3 beta), present in the Alzheimer's pathway. Polymorphisms in Gsk3b were found to alter transcription and splicing and interact with tao-haplotypes to modify disease risk in Parkinson's [28] .
Gene ontology analysis and protein-protein interaction
In this section we investigate the ontology annotations of the biomarkers present in the signatures and of the proteins most likely to bind with them. Using the biomarkers in each of the signatures -the one from Brown et al. (2002) and the three in Figure 2 we determined the most common ontologies. Interestingly, there is a general absence of brain-related annotations; the majority is metabolism-related (protein, glycogen, sulphates, hormone, among others). With this result, we went one step further and using the GATHER protein binding database, we obtained the list of proteins most likely (pvalue < 0.01) to bind with the genes in the four signatures (see Figure 4) . From these results, we can conclude that when looking at the whole brain at once, the proteins that better differentiate PD and normal brains are indeed related to brain functions, such as synapsis and neurogenesis. For the right and left hemispheres however, differentiation occurs via other mechanisms, related to metabolism, transcription and oxidative response. Supporting this conclusion, a recent study has put some light on asymmetries in PD, stating that metabolism and oxidative response variations between the two hemispheres of the brain could affect differently the dopaminergic neurons in the substantia nigra, resulting in asymmetric clinical effects [29] . However, the authors do not find an appropriate explanation for side preference in terms of symptoms and argue that the mechanisms behind side differentiation are still too complex to understand.
CONCLUSION
In this paper, we present three sets of biomarkers for Parkinson's disease (PD) using eDNA microarray data extracted from two C57BL/6J strain rodents. The first signature was obtained comparing the samples of the whole brain of the PD-affected against a control mouse. The second and third used the samples extracted from the left and right hemispheres of the brains, respectively. The problem of finding the signatures was modeled as a MIN (a,/3)-FEATURE SELECTION problem. A pathway analysis conducted on the three signatures and on the biomarkers reported in Brown et al. (2002) indicate that the MIN (a,/3)-FS approach retrieves biomarkers belonging to pathways more relevant to PD, including the Parkinson's and the Alzheimer's diseases pathways. Also, we made a study on the ontology of the biomarkers and of their most relevant binding proteins. The analysis shows that the biomarkers have mostly metabolism-related ontologies, whereas their binding proteins show more variation, with the presence not only of brain-related, but also metabolism, transcription and oxidative response ontologies.
